Search
for
Sort by
Research 30 of 1000+
- Long-term safety and efficacy of Latisse (bimatoprost 0.03% solution) for treatment of eyelash hypotrichosis in subjects with chemotherapy induced and idiopathic hypotrichosis
- Long‐term safety and efficacy of bimatoprost solution 0·03% application to the eyelid margin for the treatment of idiopathic and chemotherapy‐induced eyelash hypotrichosis: a randomized controlled trial
- Isolated long white eyelash: An underrecognized trichologic finding
- Lady with Long Eyelashes…!
- Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO‐LT phase 3, open‐label study
- Long‐Term Real‐World Outcomes of Baricitinib in Severe Alopecia Areata: A 104‐Week Retrospective Analysis From a Single Institute
- Efficacité à long terme du baricitinib dans le traitement de la pelade : résultats à la semaine 104 des études BRAVE-AA1 et BRAVE-AA2
- Effects of a New Eyelid Shampoo on Lid Hygiene and Eyelash Length in Patients with Meibomian Gland Dysfunction: A Comparative Open Study
- CLINICAL AND LABORATORY EVALUATION OF AIDS TRICHOPATHY
- A CLINICAL STUDY OF MUCOCUTANEOUS MANIFESTATIONS OF HIV
- Chemotherapy and Cutaneous Drug Reactions
- Effets secondaires cutanéo-muqueux des nouvelles molécules anticancéreuses: Inhibiteurs de l'EGF-R, inhibiteurs de tyrosine kinase et stabilisateurs du fuseau mitotique
- BC06: Efficacy of lasers and light‐based devices in long‐term hair reduction defined by body site‐specific growth cycles: a systematic review
- Baricitinib maintains regrowth of hair, eyebrows, and eyelashes over 3 years
- Eyelash Length in Children and Adolescents with Allergic Diseases
- 52709 Patient-Reported Outcomes for Scalp, Eyebrow and Eyelash Hair Loss in Patients with Severe Alopecia Areata Treated with Baricitinib: 152 Week Results from two Phase 3 Clinical Trials
- Long‐Term Follow‐Up of Previously Reported Case of Trichomegaly Associated with Alopecia Areata in a 3‐Year‐Old Girl
- Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata
- Baricitinib for the treatment of severe alopecia areata: results from a 52-week multicenter retrospective real-world study
- Continued treatment with baricitinib results in meaningful scalp responses among scalp non‐responder patients with eyebrow/eyelash regrowth in the first year
- Isolated eyebrow and eyelash trichotillomania mimicking alopecia areata
- Eyebrow and Eyelash Transplantation Using Chalazion Forceps (Dr. Min’s Method) and Importance of Post-Transplant Recovery in Hair Restoration
- 49690 Long-term efficacy of baricitinib in alopecia areata: 3-year results from BRAVE-AA1 and BRAVE-AA2
- Efficacy and Safety of Long‐Term Azathioprine Therapy for Severe Alopecia Areata: A 10‐Year Cohort Study
- Sustained Scalp, Eyebrow, and Eyelash Hair Regrowth with Ritlecitinib Through Week 48 in Patients with Alopecia Areata: Post-Hoc Analysis of the ALLEGRO Phase 2b/3 Study
- Updated Integrated Efficacy Analysis of Ritlecitinib Up to 3 Years in Adolescents With Alopecia Areata From the ALLEGRO Clinical Trials
- Baricitinib: A Review in Severe Alopecia Areata
- Is There a Role for Radiofrequency Devices in Hair?
- Upadacitinib for the Management of Alopecia Totalis and Subtotalis in Pediatric Patients: A Case Series
- Efficacy and Safety of Ritlecitinib in the Asian Subpopulation of the ALLEGRO ‐2b/3 and ALLEGRO ‐ LT Clinical Studies for Alopecia Areata